Olga Danilchanka, Ph.D.

Since joining MRL Ventures Fund in 2018, Olga Danilchanka has focused on preclinical stage investments, championing companies that harness cutting-edge biology to devise therapeutic solutions in significant unmet medical arenas. Currently, she serves as a Director on the boards of Therini Bio and as an Observer on the board of Ambagon Therapeutics and PAQ Therapeutics. Olga’s previous board experiences include Eyebiotech Limited (EyeBio, acquired by Merck & Co., Inc., Rahway, NJ, USA), Caraway Therapeutics (acquired by Merck & Co., Inc., Rahway, NJ, USA), HotSpot Therapeutics and Lava Therapeutics (NASDAQ: LAVA). Before her work with MRLV, Olga expanded her operational and scientific expertise at both Epiva Biosciences, a Flagship Pioneering newco, and the MRL Cambridge Exploratory Science Center, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. She holds a PhD from the University of Alabama at Birmingham and completed her postdoctoral training at Harvard Medical School.